Should You Go Up to 5mg Mounjaro? A Step-by-Step Guide

2.5mg is the mandatory starting dose on the licensed UK schedule — it is a tolerability step, not a treatment level.
The standard interval before moving to 5mg is four weeks, matching the pen's four-dose design.
Side effects (mainly nausea, stomach upset, fatigue) are most common at the start and after dose increases, then typically settle.
A prescriber (not you alone) decides whether the move to 5mg is appropriate based on tolerance, weight progress and your overall health picture.

Going up to 5mg Mounjaro is the natural next step after four weeks on the 2.5mg starting dose, provided you have tolerated that first pen well. The 2.5mg pen exists purely to let your body adjust — it is not a therapeutic dose, and your prescriber will expect to review whether moving up makes sense once that period is complete. That decision is always a clinical one. Mounjaro (tirzepatide) is a prescription-only medicine, so any dose change happens only with a prescriber's sign-off, not by simply ordering the next strength.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The practical process: from 2.5mg to 5mg and what shapes that decision

Step 1: finishing your 2.5mg pen and what 'tolerating it well' actually means

Most people start Mounjaro at 2.5mg and spend roughly four weeks there, one pen, four weekly injections. The purpose of that period is straightforward: it gives your gut time to get used to tirzepatide's effect on gastric emptying and appetite signalling before the dose climbs. Nausea, loose stools and a reduced appetite are all common at this stage, and they are not a sign that something has gone wrong.

Tolerating 2.5mg well does not mean feeling absolutely nothing. It means the side effects, if any, have been manageable, not severe, not persistent into week three or four, and not affecting your ability to eat, drink or function day to day. If you had a rough week two and then settled, that generally counts as tolerating the starter dose. If you are still experiencing persistent vomiting or significant distress by week four, that is a conversation for your prescriber before you move on.

One misconception worth clearing up gently: some people assume that if they have lost very little weight on 2.5mg, the dose is not working and they should rush straight past 5mg. In reality, meaningful weight loss at the starting dose was never the goal, the titration schedule exists for a reason, and the therapeutic effect builds as the dose increases over subsequent months. The Mounjaro overview covers how the full schedule is designed.

Step 2: the clinical review that gates the dose change

When should you go up to 5mg Mounjaro? The licensed titration schedule sets the minimum interval at four weeks, and your prescriber uses that review point to assess a few things: how well you tolerated 2.5mg, whether there are any new symptoms to consider, and whether dose escalation is appropriate given your current health status.

At nume, every repeat order and every dose change is reviewed by a GPhC-registered prescriber before it is approved, a real clinician reading your notes, not automated software. Patients requesting a dose increase are asked to provide evidence of current weight, which allows the prescriber to see progress and context together. You can read more about how our clinical team approaches these decisions on the clinical team page.

The practical question of when to go up to 5mg Mounjaro also has a logistical answer: you place your repeat request as your fourth injection on 2.5mg approaches, so the 5mg pen is ready for week five without a gap. A gap in dosing is not ideal, so timing matters. The considerations around moving to 5mg go into more detail on what prescribers look for.

The BNF entry for tirzepatide sets out the licensed dosing schedule for prescribers; it confirms the standard four-week minimum between steps.

Step 3: what to expect once you are on 5mg

The 5mg dose is the first genuinely therapeutic step in the Mounjaro schedule. Many people notice a more pronounced reduction in appetite compared with 2.5mg, and weight loss often becomes more measurable. Nausea and other gastrointestinal effects can return briefly as your system adjusts to the higher dose, this is normal, and the pattern tends to mirror what happened at 2.5mg, usually settling within one to two weeks.

Staying well hydrated, eating smaller meals and not skipping food entirely all help. Protein intake in particular matters: when appetite falls sharply, it is easy to under-eat quality protein, which can affect how your body handles weight loss over the longer term. If side effects at 5mg are unmanageable, contact your prescriber rather than self-managing through them. Adjustments exist for a reason.

It is also worth knowing that 5mg is not the ceiling. The licensed UK schedule continues through 7.5mg, 10mg, 12.5mg and 15mg in four-week steps, always subject to clinical review. If you are thinking ahead, the page on whether to move up to 7.5mg covers what comes next, and if you are already on 7.5mg and wondering about the step above that, there is guidance on moving to 10mg worth reading too. The NHS page on tirzepatide also gives a clear patient-level summary of the dose schedule and common side effects worth bookmarking.

When the answer might be: not yet

There are circumstances where moving to 5mg is the right next dose but not the right next step right now. Ongoing significant nausea, a recent illness that left you dehydrated, a planned surgical procedure in the near term, or a new medication that your prescriber has not yet had chance to review alongside tirzepatide, any of these can be reason to hold at 2.5mg for an additional period.

Dose escalation is not a race. The SURMOUNT-1 trial, which reported average body-weight reductions of around 20–21% at 15mg over 72 weeks, involved a full gradual titration from the starting dose, results were not achieved by rushing the schedule. If you are wondering whether to up your dose of Mounjaro at all, our guide to going up a dose on Mounjaro covers the factors worth weighing before making that call, and the FAQs address some of the more common concerns. For anything specific to your situation, the right move is to speak with your prescriber directly. The free consultation is the place to raise it and have a qualified clinician review your case.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions